Seiji Nishino
#42,869
Most Influential Person Now
Japanese psychologist
Seiji Nishino's AcademicInfluence.com Rankings
Seiji Nishinopsychology Degrees
Psychology
#3506
World Rank
#3953
Historical Rank
Cognitive Psychology
#442
World Rank
#459
Historical Rank
Download Badge
Psychology
Seiji Nishino's Degrees
- PhD Psychology Stanford University
- Masters Psychology Stanford University
- Bachelors Psychology Stanford University
Similar Degrees You Can Earn
Why Is Seiji Nishino Influential?
(Suggest an Edit or Addition)According to Wikipedia, Seiji Nishino is a Japanese neuroscientist and writer. He is a professor emeritus of psychiatry and behavioral sciences at the Stanford University. He is also the director of Stanford Center for Sleep Sciences and Medicine.
Seiji Nishino's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene (1999) (2455)
- A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains (2000) (1952)
- Hypocretin (orexin) deficiency in human narcolepsy (2000) (1651)
- Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle (2009) (1100)
- The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. (2002) (1019)
- Tuning arousal with optogenetic modulation of locus coeruleus neurons (2010) (718)
- Dopaminergic Role in Stimulant-Induced Wakefulness (2001) (708)
- Fluctuation of extracellular hypocretin‐1 (orexin A) levels in the rat in relation to the light–dark cycle and sleep–wake activities (2001) (428)
- PHARMACOLOGICAL ASPECTS OF HUMAN AND CANINE NARCOLEPSY (1997) (412)
- CSF hypocretin/orexin levels in narcolepsy and other neurological conditions (2001) (389)
- Basal forebrain circuit for sleep-wake control (2015) (341)
- Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders (2002) (334)
- Modafinil binds to the dopamine uptake carrier site with low affinity. (1994) (311)
- Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. (2005) (309)
- The Transcriptional Repressor DEC2 Regulates Sleep Length in Mammals (2009) (307)
- Muscleblind-like 2-Mediated Alternative Splicing in the Developing Brain and Dysregulation in Myotonic Dystrophy (2012) (288)
- Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects (2003) (236)
- Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation (2001) (222)
- Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. (1998) (187)
- Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. (2012) (175)
- CSF hypocretin‐1 (orexin‐A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia (2002) (175)
- Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children. (2010) (172)
- Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. (2003) (163)
- Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features (2012) (160)
- Hypocretin Levels in Sporadic and Familial Cases of Canine Narcolepsy (2001) (159)
- Clinical and neurobiological aspects of narcolepsy. (2007) (156)
- CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. (2009) (147)
- Lesions of the suprachiasmatic nucleus eliminate the daily rhythm of hypocretin-1 release. (2004) (145)
- Relationship between CSF hypocretin levels and hypocretin neuronal loss (2003) (141)
- Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. (2009) (139)
- Increased level of salivary prostaglandins in patients with major depression (1988) (136)
- Histamine H3 receptor antagonists: from target identification to drug leads. (2007) (125)
- Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs (2001) (125)
- Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke (2001) (123)
- Normal hypocretin-1 levels in Parkinson’s disease patients with excessive daytime sleepiness (2002) (121)
- A PERIOD3 variant causes a circadian phenotype and is associated with a seasonal mood trait (2016) (120)
- The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. (2006) (116)
- Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy (2001) (113)
- Narcolepsy: genetic predisposition and neuropharmacological mechanisms. REVIEW ARTICLE. (2000) (112)
- Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis (2004) (112)
- Emerging therapies in narcolepsy-cataplexy. (2005) (109)
- The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A). (2003) (104)
- Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. (2009) (102)
- Greatly increased numbers of histamine cells in human narcolepsy with cataplexy (2013) (100)
- Sleep/wake fragmentation disrupts metabolism in a mouse model of narcolepsy (2007) (100)
- Enhanced antinociception by intracerebroventricularly and intrathecally-administered orexin A and B (hypocretin-1 and -2) in mice (2005) (98)
- Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C. (2003) (94)
- Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. (1995) (94)
- The diurnal rhythm of hypocretin in young and old F344 rats. (2004) (93)
- Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine (1996) (89)
- Orexin neurons are necessary for the circadian control of REM sleep. (2009) (88)
- Salivary prostaglandin concentrations: possible state indicators for major depression. (1989) (88)
- Hypocretin deficiency in Prader–Willi syndrome (2005) (85)
- Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy (1995) (84)
- Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers (2005) (84)
- Addiction and Arousal: Alternative Roles of Hypothalamic Peptides (2006) (82)
- The hypocretin/orexin system in health and disease (2003) (82)
- Dopamine D2 mechanisms in canine narcolepsy (1991) (79)
- Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. (1993) (78)
- Neuronal defects in a human cellular model of 22q11.2 deletion syndrome (2020) (78)
- Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans (2000) (78)
- CSF hypocretin levels in Guillain–Barré syndrome and other inflammatory neuropathies (2003) (76)
- Polymorphisms within the canine MLPH gene are associated with dilute coat color in dogs (2005) (76)
- Effects of Thyrotropin-Releasing Hormone and Its Analogs on Daytime Sleepiness and Cataplexy in Canine Narcolepsy (1997) (72)
- Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome (2002) (72)
- Hypocretin-1 (orexin-A) levels in human lumbar CSF in different age groups: infants to elderly persons. (2002) (70)
- Increased hypocretin-1 levels in cerebrospinal fluid after REM sleep deprivation (2004) (70)
- A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor (2001) (70)
- Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems (1993) (67)
- Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of d- and l-derivatives in canine narcolepsy (2000) (67)
- Hypocretin/orexin and narcolepsy: new basic and clinical insights (2010) (67)
- Cholinergic mechanisms in canine narcolepsy—I. Modulation of cataplexy via local drug administration into the pontine reticular formation (1994) (58)
- Major Histocompatibility Class II Molecules in the CNS: Increased Microglial Expression at the Onset of Narcolepsy in a Canine Model (1996) (57)
- Diurnal variation in CSF orexin-A in healthy male subjects. (2006) (56)
- Histamine from Brain Resident MAST Cells Promotes Wakefulness and Modulates Behavioral States (2013) (56)
- Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. (1993) (55)
- Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice. (2010) (55)
- Measurement of hypocretin/orexin content in the mouse brain using an enzyme immunoassay: the effect of circadian time, age and genetic background (2002) (55)
- CSF versus serum leptin in narcolepsy: is there an effect of hypocretin deficiency? (2006) (54)
- Hypocretin deficiency in familial symptomatic narcolepsy (2001) (54)
- The hypothalamic peptidergic system, hypocretin/orexin and vigilance control (2007) (52)
- An activation of parvocellular oxytocinergic neurons in the paraventricular nucleus in oxytocin-induced yawning and penile erection (2006) (52)
- Neuropharmacology and neurochemistry of canine narcolepsy. (1994) (51)
- Development of Cataplexy in Genetically Narcoleptic Dobermans (1998) (51)
- CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture (2002) (49)
- CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders (2004) (49)
- Enhanced antinociception by intracerebroventricularly administered orexin A in histamine H1 or H2 receptor gene knockout mice (2005) (48)
- Sex difference in body weight gain and leptin signaling in hypocretin/orexin deficient mouse models (2006) (48)
- Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of rapid eye movement sleep. (1990) (48)
- Recent Advances in the Treatment of Narcolepsy (2011) (48)
- Chronic Oral Administration of CG-3703, a Thyrotropin Releasing Hormone Analog, Increases Wake and Decreases Cataplexy in Canine Narcolepsy (2000) (48)
- Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. (2010) (48)
- Sulpiride, a D2/D3 Blocker, Reduces Cataplexy but not REM Sleep in Canine Narcolepsy (2000) (43)
- The orexin/hypocretin system : physiology and pathophysiology (2006) (43)
- The Pathophysiologic Basis of Secondary Narcolepsy and Hypersomnia (2011) (42)
- Sleep and EEG features in genetic models of Down syndrome (2008) (42)
- Neuropharmacological Characterization of Basal Forebrain Cholinergic Stimulated Cataplexy in Narcoleptic Canines (1998) (41)
- Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats (2003) (40)
- Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. (2008) (40)
- Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice (2009) (38)
- The hypocretin/orexin receptor: therapeutic prospective in sleep disorders (2007) (38)
- Amyloid- b Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle (2009) (38)
- Narcolepsy caused by acute disseminated encephalomyelitis. (2004) (37)
- Acute effects of zolpidem on daytime alertness, psychomotor and physical performance (2007) (37)
- The Sleep-Promoting and Hypothermic Effects of Glycine are Mediated by NMDA Receptors in the Suprachiasmatic Nucleus (2015) (36)
- Hypocretin‐1 (orexin‐A) concentrations in cerebrospinal fluid are low in patients with Guillain–Barré syndrome (2002) (35)
- CSF histamine levels in rats reflect the central histamine neurotransmission (2008) (34)
- Central α1 adrenoceptor subtypes in narcolepsy-cataplexy: a disorder of REM sleep (1989) (34)
- Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and controls: relationship to sleep architecture (1998) (34)
- Chapter 38 – Wake-Promoting Medications: Basic Mechanisms and Pharmacology (2005) (34)
- Canine narcolepsy is associated with an elevated number of α2-receptors in the locus coeruleus (1989) (34)
- Narcolepsy: pathophysiology and pharmacology. (2007) (33)
- Emerging treatments for narcolepsy and its related disorders (2010) (32)
- Hypersomnolence and increased REM sleep with low cerebrospinal fluid hypocretin level in a patient after removal of craniopharyngioma. (2005) (31)
- Narcolepsy and syndromes of primary excessive daytime somnolence. (2004) (30)
- Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep [corrected]. (1999) (30)
- Decline of CSF orexin (hypocretin) levels in Prader–Willi syndrome (2016) (30)
- Transient total sleep loss in cerebral Whipple's disease: a longitudinal study (2002) (29)
- Cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by M2 muscarinic receptors. (1994) (29)
- Narcoleptic canines display periodic leg movements during sleep (2001) (28)
- The roles of midbrain and diencephalic dopamine cell groups in the regulation of cataplexy in narcoleptic Dobermans (2004) (28)
- An overview of hypocretin based therapy in narcolepsy (2018) (27)
- Narcolepsy and cataplexy. (2011) (27)
- Hypothalamus, hypocretins/orexin, and vigilance control. (2011) (27)
- Article reviewed: Plasma orexin-A is lower in patients with narcolepsy. (2002) (26)
- Hypocretin Ligand Deficiency in Narcolepsy: Recent Basic and Clinical Insights (2010) (25)
- Circadian distribution of rest/activity in narcoleptic and control dogs: assessment with ambulatory activity monitoring (1997) (25)
- Armodafinil for excessive daytime sleepiness. (2008) (25)
- Effects of SDZ NVI-085, a putative subtype-selective alpha 1-agonist, on canine cataplexy, a disorder of rapid eye movement sleep. (1991) (24)
- Prostaglandin E2 and its methyl ester reduce cataplexy in canine narcolepsy. (1989) (23)
- Pharmacologic Management of Excessive Daytime Sleepiness. (2022) (22)
- Expression pattern of FOS in orexin neurons during sleep induced by an adenosine A2A receptor agonist (2006) (22)
- HLA and hypocretin studies in Korean patients with narcolepsy. (2002) (22)
- CSF orexin A concentrations and expressions of the orexin-1 receptor in rat hippocampus after cardiac arrest (2006) (21)
- Inhibition of rostral basal forebrain neurons promotes wakefulness and induces FOS in orexin neurons (2003) (20)
- Review of pathophysiology and clinical management of narcolepsy in dogs (2007) (20)
- Conditions of primary excessive daytime sleepiness. (2005) (20)
- HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy (2019) (20)
- Mistaken diagnosis of psychogenic gait disorder in a man with status cataplecticus ("Limp Man Syndrome") (2004) (19)
- CSF hypocretin-1/orexin-A concentrations in patients with subarachnoid hemorrhage (SAH) (2005) (19)
- Inheritance of von Willebrand's disease in a colony of Doberman Pinschers. (2000) (19)
- Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep. (1999) (19)
- FOS expression in orexin neurons following muscimol perfusion of preoptic area (2004) (18)
- Dr. Nishino Replies (1989) (18)
- Hypersomnia and low cerebrospinal fluid hypocretin levels in acute disseminated encephalomyelitis. (2004) (18)
- Association between heart rate variability, blood pressure and autonomic activity in cyclic alternating pattern during sleep. (2014) (17)
- Drug Treatment of Patients with Insomnia and Excessive Daytime Sleepiness (1999) (17)
- Time–course of cerebrospinal fluid histamine in the wake‐consolidated squirrel monkey (2012) (17)
- Loss of polyubiquitin gene Ubb leads to metabolic and sleep abnormalities in mice (2009) (16)
- Central alpha 1 adrenoceptor subtypes in narcolepsy-cataplexy: a disorder of REM sleep. (1989) (16)
- Canine narcolepsy is associated with an elevated number of alpha 2-receptors in the locus coeruleus. (1989) (16)
- N-Methyl-D-aspartate receptor antibody could be a cause of catatonic symptoms in psychiatric patients: case reports and methods for detection (2017) (16)
- Breeding history of the Stanford colony of narcoleptic dogs (1998) (16)
- Measurement of cerebrospinal fluid orexin‐A (hypocretin‐1) by enzyme‐linked immunosorbent assay: A comparison with radioimmunoassay (2018) (15)
- Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy. (1996) (15)
- Mesopontine organization of cholinergic and catecholaminergic cell groups in the normal and narcoleptic dog (1997) (15)
- Familial narcolepsy in the Lipizzaner horse: a report of three fillies born to the same sire (2012) (15)
- Mesopontine organization of cholinergic and catecholaminergic cell groups in the normal and narcoleptic dog. (1997) (15)
- Residual effects of zolpidem, triazolam, rilmazafone and placebo in healthy elderly subjects: a randomized double-blind study. (2015) (14)
- Systematic evaluation of personal genome services for Japanese individuals (2013) (13)
- Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation (2018) (12)
- Neuronal activity in the cholinoceptive basal forebrain of freely moving narcoleptic dobermans (1998) (12)
- Wake-promoting effects of ONO-4127Na, a prostaglandin DP1 receptor antagonist, in hypocretin/orexin deficient narcoleptic mice (2016) (12)
- Tasimelteon for treating non-24-h sleep-wake rhythm disorder (2019) (12)
- Pharmacologic Management of Excessive Daytime Sleepiness. (2017) (12)
- Mast cell involvement in glucose tolerance impairment caused by chronic mild stress with sleep disturbance (2017) (12)
- Modes of Action of Drugs Related to Narcolepsy: Pharmacology of Wake-Promoting Compounds and Anticataplectics (2010) (12)
- Analysis of onset location, laterality and propagation of cataplexy in canine narcolepsy (2002) (11)
- Low cerebrospinal fluid hypocretin levels found in familial narcolepsy. (2001) (11)
- CSF orexin-A/hypocretin-1 concentrations in patients with intracerebral hemorrhage (ICH) (2008) (11)
- Effect of 5-HT1A receptor agonists and antagonists on canine cataplexy. (1995) (11)
- The Orexin/Hypocretin System (2005) (9)
- Reduced expression of TAC1, PENK and SOCS2 in Hcrtr-2 mutated narcoleptic dog brain (2007) (9)
- Prostaglandin E2 levels in cerebrospinal fluid of normal and narcoleptic dogs (1990) (9)
- High rebound mattress toppers facilitate core body temperature drop and enhance deep sleep in the initial phase of nocturnal sleep (2018) (8)
- Hypocretin stimulates [35S]GTPγS binding in Hcrtr 2-transfected cell lines and in brain homogenate (2002) (8)
- The neurochemistry of awakening: findings from sleep disorder narcolepsy. (2010) (8)
- Overview of Management of Narcolepsy (2010) (7)
- Neuropeptides as possible targets in sleep disorders (2007) (7)
- Noninvasive detection of sleep/wake changes and cataplexy-like behaviors in orexin/ataxin-3 transgenic narcoleptic mice across the disease onset (2014) (7)
- Neuropeptides as possible targets in sleep disorders: special emphasis on hypocretin-deficient narcolepsy. (2007) (7)
- Hypocretin Measurements in the CSF, and Blood and Brain Tissue (2006) (7)
- Chronic Powder Diet After Weaning Induces Sleep, Behavioral, Neuroanatomical, and Neurophysiological Changes in Mice (2015) (7)
- Relationship of orexin (hypocretin) system and astrocyte activation in Parkinson’s disease with hypersomnolence (2015) (7)
- Detailed evaluation of the upper airway in the Dp(16)1Yey mouse model of Down syndrome (2020) (6)
- Apnea during Cheyne-Stokes-like breathing detected by a piezoelectric sensor for screening of sleep disordered breathing (2015) (6)
- Advances in the pharmacological management of non-24-h sleep-wake disorder (2021) (6)
- Intraperitoneal injection of ginkgolide B, a major active compound of Ginkgo biloba, dose-dependently increases the amount of wake and decreases non-rapid eye movement sleep in C57BL/6 mice (2020) (6)
- Narcolepsy in a hypocretin/orexin-deficient chihuahua (2003) (6)
- Effect of Uneven Acaricide Application on Effective Control of Spider Mites in Chrysanthemum Fields. (1998) (5)
- Central administration of vitamin B12 aggravates cataplexy in canine narcolepsy (1997) (5)
- 精神科におけるanti-NMDAR脳炎：悪性緊張病と非定型精神病と電気治療 (2014) (5)
- Neurotransmitters and Neuropharmacology of Sleep/Wake Regulations (2013) (5)
- Increased body-mass index in patients with narcolepsy (2000) (4)
- Neurochemistry and Biomarkers of Narcolepsy and Other Primary and Secondary Hypersomnias (2012) (4)
- History and perspectives of hypocretin/orexin research in sleep medicine (2003) (4)
- Toward the Next-Generation Sleep Monitoring / Evaluation by Human Body Vibration Analysis (2016) (4)
- Narcolepsy and Syndromes of Central Nervous System-Mediated Sleepiness (2005) (4)
- Hypocretin/Orexin Replacement Therapy in Hypocretin/Orexin-Deficient Narcolepsy (2006) (4)
- Rebound hypersomnolence, stimulant abuse, and DAT-mediated dopamine release. (2009) (3)
- Thalidomide, immune modulation and narcolepsy. (1996) (3)
- Refeeding after a 24-hour fasting deepens NREM sleep in a time-dependent manner (2011) (3)
- [Anti-NMDA encephalitis in psychiatry; malignant catatonia, atypical psychosis and ECT]. (2014) (3)
- Stimulants in Excessive Daytime Sleepiness (2010) (3)
- Evaluations of effects of high rebound and low rebound mattress pads on nocturanl sleep and its associated physiology (2013) (3)
- Platelet α2 adrenoceptors in human and canine narcolepsy (1991) (2)
- Canine Models of Narcolepsy (2006) (2)
- Neurobiology of Narcolepsy (1998) (2)
- The Canine Model of Narcolepsy (2005) (2)
- Sake yeast induces the sleep-promoting effects under the stress-induced acute insomnia in mice (2021) (2)
- Intracranial mast cells contribute to the control of social behavior in male mice (2021) (2)
- Hypocretin stimulates [(35)S]GTP gamma S binding in Hcrtr 2-transfected cell lines and in brain homogenate. (2002) (2)
- A rare genetic variant in the cleavage site of prepro-orexin is associated with idiopathic hypersomnia (2022) (2)
- Clinical Experience with a Dual Orexin Receptor Antagonist, Suvorexant (Belsomra) in Japan (2018) (2)
- Factors Associated with Excessive Daytime Sleepiness in Obstructive Sleep Apnea Syndrome under CPAP Treatment (2012) (2)
- [The US Government's effort in decreasing the cost of sleep-related problems and its outcome]. (2008) (1)
- Effect of Acaricide Application on Two-Spotted Spider Mite(Green-Form) on Chrysanthemum. (1998) (1)
- Modulations of Ventral Tegmental Area (VTA) Dopaminergic Neurons by Hypocretins/Orexins: Implications in Vigilance and Behavioral Control (2016) (1)
- “Atypical psychoses” and anti‐NMDA receptor encephalitis: A review of literature in the mid‐twentieth century (2021) (1)
- Sleep and the glymphatic system (2021) (1)
- Vagus nerve stimulation modulates cataplexy in narcoleptic dogs (2003) (1)
- Comparison of Solriamfetol and Modafinil on Arousal and Anxiety-Related Behaviors in Narcoleptic Mice (2022) (1)
- Modafinil and neuropharmacology of narcolepsy (2008) (1)
- Potential role of orexin in the pathogenesis of Alzheimer's disease (2013) (1)
- Symptomatic Narcolepsy or Hypersomnolence with and Without Hypocretin (Orexin) Deficiency (2010) (1)
- Residual effects of low dose of suvorexant, zolpidem, and ramelteon in healthy elderly subjects: A randomized double‐blind study (2022) (1)
- Histamine in Narcolepsy and Excessive Daytime Sleepiness (2011) (1)
- Hypocretin/Orexin Tonus and Vigilance Control (2006) (1)
- Occurrence of rice stinkbugs on centipede grass planted in rice field ridge (2006) (1)
- Evaluations of effects of sleep surfaces on athletic performance in youth (2020) (1)
- Underpinning and Large Underground Excavation Work at Kyoto Subway Tozai Line-Misasagi Station Works (1996) (1)
- BMAL1 loss in oligodendroglial lineage cells dysregulates myelination and sleep (2022) (1)
- Advances in pharmaceutical treatment options for narcolepsy (2018) (1)
- Free Communication Abstracts (2005) (1)
- Genetic and demographic predisposing factors associated with pediatric sleepwalking in the Philadelphia Neurodevelopmental Cohort (2021) (1)
- Chapter 44 – Wake-Promoting Medications: Basic Mechanisms and Pharmacology (2011) (1)
- HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy (2019) (0)
- Sleepiness: Neurochemistry of excessive sleepiness (2011) (0)
- A rare genetic variant in the cleavage site of prepro-orexin is associated with idiopathic hypersomnia (2022) (0)
- The Genetic Basis of Sleep and Sleep Disorders: Orexin (hypocretin) and narcolepsy (2013) (0)
- Narcolepsy: Neuropharmacological Aspects (2007) (0)
- CAFFEINE, IN THE FORM OF CAFFEINE-CONTAINING BEVERAGES OR OVER-THE-COUNTER CAFFEINE TAB- (2010) (0)
- Reply (2002) (0)
- Frequency-Based Sleep Stage Detections by Single EEG Derivation in Healthy Human Subjects (2012) (0)
- Altered responses of end‐expiratory lung volume and upper airway patency to body posture in diet‐induced obese mice (2021) (0)
- P4-081: Diurnal fluctuation of amyloid-β in the brain interstitial fluid of young Tg2576 mice (2008) (0)
- Pharmacologic Management of Excessive Daytime Sleepiness. (2022) (0)
- Color Measuring in Landscape According to Weather and Time (1997) (0)
- EDS in Parkinson’s disease: pharmacology and new mouse model (2013) (0)
- Mast cell involvement in glucose tolerance impairment caused by chronic mild stress with sleep disturbance (2017) (0)
- Levels of hypocretin-1 (orexin A) in the cerebrospinal fluid of two young hypersomniacs suspected of being narcoleptic (2003) (0)
- Serum prolactin response to a D2 antagonist in narcoleptic and control canines. (1992) (0)
- NARCOLEPSY IS A SLEEP DISORDER CHARACTERIZED BY EXCESSIVE DAYTIME SLEEPINESS, CATAPLEXY, SLEEP PARALYSIS, ABNORMAL RAPID EYE MOVEMENT (REM) SLEEP OCCURRENCE AT SLEEP ONSET, AND HYP- (2004) (0)
- ANTI-NMDA-RECEPTOR ANTIBODY DETECTED IN LIMBIC ENCEPHALITIS, SCHIZOPHRENIA AND NARCOLEPSY WITH PSYCHOTIC SYMPTOMS (2014) (0)
- 0518 Sleep Facilitation by Artificial Carbonated Bathing in Healthy Elderly; EEG, Core, Proximal, and Distal Temperature Evaluations (2020) (0)
- Futures in Sleep Research and Medicine (2014) (0)
- Narcolepsy and Idiopathic Hypersomnia (2015) (0)
- The anticataplectic and REM suppression effect of milnacipran, an SNRI, on human and canine narcolepsy (2021) (0)
- The pathogenesis of narcolepsy, current treatments and prospective therapeutic targets (2016) (0)
- Brain Mast Cells in Sleep and Behavioral Regulation. (2022) (0)
- The kinetics of orexin-A/hypocretin-1 in stroke - Clinical and basic investigations (2007) (0)
- SYMPATHETIC AND PARASYMPATHETIC CONTROL OF HEART RATE RESPONSE TO RESTRAINT STRESS DURING THE VULNERABLE PERIOD IN NEWBORN RATS (2013) (0)
- Social stress alters sleep in FGF21-deficient mice (2022) (0)
- Narcolepsy and other non‐SAS hypersomnia in sleep breathing disorders clinic (2001) (0)
- [An old and new focal symptom, hypothalamus and hypersomnia, orexin system and narcolepsy]. (2005) (0)
- 0322 PLASMA AMINO ACID CHANGES IN PATIENTS WITH INSOMNIA AND SLEEP DISORDERS BREATHING (2017) (0)
- Clinical application to obstructive sleep apnea syndrome of the upper airway computer fluid dynamics (2015) (0)
- The Genetic Basis of Sleep and Sleep Disorders: Genetic disorders producing symptomatic narcolepsy (2013) (0)
- Narcolepsy–Cataplexy Syndrome and Symptomatic Hypersomnia (2015) (0)
- Author's response to reviews Title: Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features Authors: (2012) (0)
- Abstracts for the 6th Congress of Asian Sleep Research Society (2009) (0)
- The effects of sleep on the cardiovascular and the thermoregulatory systems – possible role for hypocretin (2009) (0)
- Neuro‐Immunological Disorders (2010) (0)
- Narcolepsy, Cataplexy, and Sleep Paralysis (2013) (0)
- 0277 ROPINIROLE AMELIORATES INSOMNIA IN A PROGRESSIVE MOUSE MODEL OF PARKINSON’S DISEASE (2017) (0)
- 0348 RESIDUAL EFFECTS OF SUVOREXANT, ZOLPIDEM AND RAMELTEON IN HEALTHY ELDERLY SUBJECTS: A RANDOMIZED DOUBLE-BLIND STUDY (2017) (0)
- Changes in sleep profile on exposure to sodium chloride and artificially carbonated springs: a pilot study (2023) (0)
- Phylogenic Analysis of Peach with SSR Markers (2015) (0)
- Types of Hypersomnias (2008) (0)
- Effect of fungicide with enviromental control on sooty mold on umbrella pine, Sciadopitys verticillata (Thumb) (2001) (0)
- Frequency-Based Sleep Stage Detections by Single (2012) (0)
- Symptomatic Narcolepsy or Hypersomnia, with and Without Orexin (Hypocretin) Deficiency (2015) (0)
- Influences of sleep and lifestyle factors on the risk for covid-19 infections, from internet survey of 10,000 Japanese business workers (2022) (0)
- Chapter 13 Narcolepsy (2005) (0)
- Deletion of histidine decarboxylase (HDC) enhances the antinociceptive effects of orexin A in the central nervous system (2004) (0)
- Hypocretin/dopamine interaction in sleep-related motor function (2004) (0)
- ROLE OF HYPOCRETIN-1,2 (OREXIN A AND B) IN PAIN PERCEPTION (2004) (0)
- 0943 DEMOGRAPHICAL AND CLINICAL FACTORS ASSOCIATED WITH PARASOMNIA IN CHILDREN: SECONDARY DATA ANALYSIS FROM THE PHILADELPHIA NEURODEVELOPMENTAL COHORT (2017) (0)
- Poster abstracts (2006) (0)
- Rapid Eye Movement Sleep: Narcolepsy and REM sleep (2011) (0)
- Sleep Length in Mammals The Transcriptional Repressor DEC 2 Regulates (2009) (0)
- Follistatin is secreted from pituitary folliculo-stellate cell lines by an ABCA1 transporter (2003) (0)
- Epoch Extension Method of EEG on the Automatic Sleep Stage Classification (2022) (0)
- Neuronal defects in a human cellular model of 22q11.2 deletion syndrome (2020) (0)
- Chapter 6 – Stimulant Pharmacology (2012) (0)
- VOLVEMENT OF THE DOPAMINERGIC SYSTEM IN THE REGULATION OF SLEEP-WAKE CYCLE, IN CON- (2009) (0)
- 0201 EFFECTS OF INTRAPERITONEAL INJECTION OF GINGKOLIDES AND BILOBALIDE ON SLEEP STUDY IN MICE (2017) (0)
- 0944 SUPERFICIAL WHITE MATTER AND CORTICAL THICKNESS ASSOCIATED WITH PARASOMNIAS IN CHILDREN (2017) (0)
- Neuroscience News (1999) (0)
- Co-localisation of ATP-binding cassette transporter 1 (ABCA1) and annexin I in folliculo-stellate cells (2002) (0)
- 0703 LOW DOSE OF ARIPIPRAZOLE REDUCED NOCTURNAL SLEEP TIME IN THE PATIENTS WITH DELAYED SLEEP PHASE DISORDER AND DEPRESSIVE SYMPTOMS. (2017) (0)
- Symposia Abstracts (2005) (0)
- Hypocretin-Deficient Narcolepsy as a Disease Model to Study the Hypothalamic Function in Health and Disease (2006) (0)
- 0378 Sleep Facilitation by an Artificially Carbonated Spring; Body Temperature, EEG and Autonomic Nervous Activity Evaluations (2018) (0)
- Oral Sessions: O3-03: Biomarkers: Temporal Sequence of Biomarkers (2013) (0)
- The anticataplectic and REM suppression effect of milnacipran, an SNRI, on human and canine narcolepsy (2021) (0)
- Platelet alpha 2 adrenoceptors in human and canine narcolepsy. (1991) (0)
- SUPRACHIASMATIC NUCLEUS IS ESSENTIAL FOR SLEEP-IMPROVING EFFECTS OF GLYCINE (2012) (0)
- Occurrence of parasites of Liriomyza trifolii (BURGESS) in Nara Prefecture. (1997) (0)
- Health Risk Narcolepsy: Evidence for an Involvement of Alpha-Adrenergic Mechanisms (1991) (0)
- Sleep phenotype characterization of peripheral and central mouse models of myotonic dystrophy (2013) (0)
- Medications that disrupt sleep (2021) (0)
- Comparsion among three application methods of the amount of pesticides deposited on leaves of chrysanthemum, and improvement of application action (1995) (0)
- 0124 Brain Resident Mast Cells Regulate Brain Histamine Content and Promote Wakefulness (2019) (0)
- Hypocretin Status in Neurological Disorders in Relation to Excessive Sleepiness and Cataplexy (2006) (0)
- S.16.01 Hypocretins and histamine in the physiology and pathology of vigilance states (2003) (0)
- Wake-promoting medications (2021) (0)
This paper list is powered by the following services:
Other Resources About Seiji Nishino
What Schools Are Affiliated With Seiji Nishino?
Seiji Nishino is affiliated with the following schools:
